Double-blind, placebo-controlled cross-over study of intravenous -adenosyl-L-methionine in patients with fibromyalgia (FM)

The objective of this study was to test the efficacy of

intravenously administered S-adenosyl-L-methionine (SAMe) in

patients with fibromyalgia (FM). Thirty-four out-patients with

fibromyalgia symptoms received SAMe 600 mg i.v. or placebo

daily for 10 days in a cross-over trial. There was no

significant difference in improvement in the primary outcome:

tender point change between the two treatment groups. There

was a tendency towards statistical significance in favour of

SAMe on subjective perception of pain at rest (p = 0.08), pain

on movement (p = 0.11), and overall well-being (p = 0.17) and

slight improvement only on fatigue, quality of sleep, morning

stiffness, and on the Fibromyalgia Impact Questionnaire for

pain. No effect could be observed on isokinetic muscle

strength, Zerrsen self-assessment questionnaire, and the face

scale. No effect of SAMe in patients with FM was found in this

short term study.

1 Star2 Stars3 Stars4 Stars5 Stars (30 votes, average: 2.95 out of 5)

Leave a Reply